Skip to main content
. 2021 Jan 26;10(3):e019045. doi: 10.1161/JAHA.120.019045

Figure 1. Kaplan‐Meier estimates of cardiovascular disease (CVD), myocardial infarction (MI), and stroke, grouped by changes in pre–diabetes mellitus.

Figure 1

A, Kaplan‐Meier estimates of CVD, grouped by changes in pre–diabetes mellitus. Individuals who reverted from pre–diabetes mellitus to normoglycemia experienced a lower risk than participants who progressed to diabetes mellitus. B, Kaplan‐Meier estimates of MI, grouped by changes in pre–diabetes mellitus. Individuals who reverted from pre–diabetes mellitus to normoglycemia experienced a lower MI risk than participants who progressed to diabetes mellitus. C, Kaplan‐Meier estimates of stroke, grouped by changes in pre–diabetes mellitus. Individuals who reverted from pre–diabetes mellitus to normoglycemia experienced a lower stroke risk than participants who progressed to diabetes mellitus. D, Kaplan‐Meier estimates of all‐cause mortality, grouped by changes in pre–diabetes mellitus. Individuals who reverted from pre–diabetes mellitus to normoglycemia experienced a lower all‐cause mortality risk than participants who progressed to diabetes mellitus.